Prof. Dr. med. Dr. med. habil. Sigmund Silber
FESC, FACC, FAHA
Kardiologe

319

Yeh RW, Silber S, Chen L, Chen S, Hiremath S, Neumann FJ, Qiao S, Saito S, Xu B, Yang Y, Mauri L.
5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program
JACC Cardiovasc Interv. 2017;10:247-254
your personal reprint


318

Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, Erglis A, Jauhar R, Popma JJ, Stoler R, Silber S
9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System
JACC Cardiovasc Interv. 2017;10:160-167
your personal reprint


317

Fajadet J, Neumann FJ, Hildick-Smith D, Petronio S, Zaman A, Spence M, Wohrle J, Elhadad S, Roberts D, Hovasse T, Valdes M, Silber S.
Twelve-Month Results of A Prospective, Multicentre Trial to Assess the Everolimus-Eluting Coronary Stent System (Promus Element): The PLATINUM PLUS All Comers Randomised Trial.
EuroIntervention. 2017;12:1595-1604
your personal reprint


316

Di Mario C, Serruys PW, Silber S, Lu S, Wang W, Widimsky P, Xu B, Windecker S.
Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program.
EuroIntervention,  2016;12:1207-1214
your personal reprint


315

Silber S, Witzenbichler B, Vester E.
Optimale orale Thrombozytenaggregationshemmung (TAH) bei Patienten mit und nach akutem Koronarsyndrom (ACS):
Wann beginnen, womit und wie lange?

Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
Update, 3. Version, Herbst 2016
your personal reprint


314

Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bansch D, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC.
Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern
Herzschrittmachertherapie & Elektrophysiologie. 2016; 27:295-306
your personal reprint 


313

Pilgrim T, Vranckx P, Valgimigli M, Stefanini GG, Piccolo R, Rat J, Rothenbuhler M, Stortecky S, Raber L, Blochlinger S, Hunziker L, Silber S, Juni P, Serruys PW, Windecker S.
Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
Am Heart J. 2016;175:56-65 
your personal reprint 


312

Abdel-Wahab M, Neumann FJ, Serruys PW, Silber S, Leon M, Mauri L, Yeung A, Belardi JA, Widimsky P, Meredith I, Saito S, Richardt G.
Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program
EuroIntervention, 2016, 12:465-472
your personal reprint


311

Piccolo R, Franzone A, Koskinas KC, Raber L, Pilgrim T, Valgimigli M, Stortecky S, Rat-Wirtzler J, Silber S, Serruys PW, Juni P, Heg D, Windecker S.
Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Am J Cardiol. 2016;118:345-352 
your personal reprint 


310

Belardi J, Manoharan G, Albertal M, Widimsky P, Neumann FJ, Silber S, Leon MB, Saito S.
The influence of age on clinical outcomes in patients treated with the resolute zotarolimus-eluting stent.
Catheter Cardiovasc Interv. 2016;87:253-261
your personal reprint


309

Koskinas KC, Siontis GC, Piccolo R, Franzone A, Haynes A, Rat-Wirtzler J, Silber S, Serruys PW, Pilgrim T, Raber L, Heg D, Juni P, Windecker S.
Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients
Circ Cardiovasc Interv. 2016;9:e003255
your personal reprint


298

Vranckx P, Kalesan B, Stefanini GG, Farooq V, Onuma Y, Silber S, de Vries T, Juni P, Serruys PW, Windecker S.
Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention.
EuroIntervention, 2015;11:171-179
your personal reprint


297

Kelbaek H, Holmvang L, Richardt G, Eberli FR, Stella P, Buszman PE, Neumann FJ, Serruys PW, Windecker S, Widimsky P, Belardi JA, Silber S.
Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions.
EuroIntervention. 2015;11:650-657
your personal reprint


296

Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P, investigators N.
Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial.
EuroIntervention. 2015;11:549-554
your personal reprint


295

Dudek D, Dziewierz A, Brener SJ, Abizaid A, Merkely B, Costa RA, Bar E, Rakowski T, Kornowski R, Dressler O, Abizaid A, Silber S, Stone GW.
Mesh-covered embolic protection stent implantation in ST-segment-elevation myocardial infarction: final 1-year clinical and angiographic results from the MGUARD for acute ST elevation reperfusion trial.
Circ Cardiovasc Interv. 2015;8:e001484
your personal reprint


294

Diletti R, Garcia-Garcia HM, Bourantas C, Van Mieghem NM, van Geuns RJ, Muramatsu T, Zhang YJ, Mauri L, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Neumann FJ, Yeung AC, Saito S, Liu M, van Leeuwen F, Serruys PW.
Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.
Catheter Cardiovasc Interv. 2015;85:952-958
your personal reprint


293

Bourantas CV, Zhang YJ, Garg S, Iqbal J, Valgimigli M, Windecker S, Mohr FW, Silber S, Vries T, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW.
Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials.
Heart, 2014;100:1158-1164
your personal reprint 


292

Vester EG, Bocksch W, Dörr R, Grebe O, Hoffmann S, Leitsch T, Silber S.
Orale Antikoagulation bei interventionellen Eingriffen in der Kardiologie,
Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
Sommer 2014 
your personal reprint 


291

Kotzerke J, Silber S.
Endovascular Brachytherapy to Prevent Restenosis After Percutaneous Coronary Intervention
Buchkapitel in: Therapeutic Nuclear Medicine, Editor: Richard P. Baum,
Springer-Verlag Berlin Heidelberg 2014, ISSN 0942-5373 
your personal reprint 


290

Witt S, Leidl R, Becker C, Holle R, Block M, Brachmann J, Silber S, Stollenwerk B.
The effectiveness of the cardiovascular disease prevention programme 'KardioPro' initiated by a German sickness fund: a time-to-event analysis of routine data.
PLoS One. 2014;9:e114720 
your personal reprint 


289

Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM for the DETECT study group.
Prognostic value of reported chest pain for cardiovascular risk stratification in primary care.
European Journal of Preventive Cardiology. 2014;21:727-738
your personal reprint 


288

Loh JP, Stella PR, Sangiorgi G, Silber S, Stahnke S, von Strandmann RP, Torguson R, Waksman R.
Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
Cardiovascular Revascularization Medicine, 2014;15:23-28
your personal reprint 


287

Aljutaili M, Becker C, Witt S, Holle R, Leidl R, Block M, Brachmann J, Silber S, Bestehorn K, Stollenwerk B.
Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data.
BMC Health Serv Res. 2014;14:263
your personal reprint 


286

Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S.
4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
J Am Coll Cardiol. 2014;63:1617-1625
your personal reprint 


285

Stefanini GG, Taniwaki M, Kalesan B, Raber L, Stortecky S, Pilgrim T, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S.
The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents.
PLoS One. 2014;9:e106450
your personal reprint 


284

Caputo R, Leon M, Serruys P, Neumann FJ, Yeung A, Windecker S, Belardi JA, Silber S, Meredith I, Widimsky P, Saito S, Mauri L.
Performance of the resolute zotarolimus-eluting stent in small vessels.
Catheter Cardiovasc Interv. 2014;84:17-23
your personal reprint 


283

Dudek D, Brener SJ, Rakowski T, Dziewierz A, Abizaid A, Silber S, Yaacoby E, Dizon JM, Costa RA, Maehara A, Dressler O, Stone GW.
Efficacy of an Embolic Protection Stent as a Function of Delay to Reperfusion in ST-Segment Elevation Myocardial Infarction (from the MASTER Trial).
Am J Cardiol. 2014;114:1485-1489
your personal reprint 


279

Widimsky P, Motovska Z, Belardi J, Serruys P, Silber S, Windecker S, Neumann FJ.
Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program.
Int J Cardiol. 2013;168:3522-3526  
your personal reprint 


278

Willich SN, Müller-Riemenschneider F, McBride D, Silber S, Kuck KH, Nienaber CA, Schneider S, Senges J, Brüggenjürgen B.
Health economic evaluation of the use of drug-eluting stents : First results from the Drug-Eluting Stent Registry (DES.de).
Herz, 2013; 38:57-64  
your personal reprint 


277

Vranckx P, McFadden E, Cutlip DE, Mehran R, Swart M, Kint PP, Zijlstra F, Silber S, Windecker S, Serruys PW.
Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation.
Contemporary Clinical Trials. 2013;34:53-59  
your personal reprint 


276

Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L.
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
JACC Cardiovasc Interv. 2013;6:366-377  
your personal reprint 


275

Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P. 
Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
JACC Cardiovasc Interv. 2013;6:905-913  
your personal reprint 


274

Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study.
Clin Res Cardiol. 2013;102:259-268  
your personal reprint 


273

Haude M, Lee SW, Worthley SG, Silber S, Verheye S, Erbs S, Rosli MA, Botelho R, Meredith I, Sim KH, Stella PR, Tan HC, Whitbourn R, Thambar S, Abizaid A, Koh TH, Den Heijer P, Parise H, Cristea E, Maehara A, Mehran R.
The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
JACC Cardiovasc Interv. 2013;6:334-343  
your personal reprint 


272

Farooq V, Vranckx P, Mauri L, Cutlip DE, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Negoita M, van Leeuwen F, Neumann FJ, Yeung AC, Garcia-Garcia HM, Serruys PW.
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program.
Heart. 2013;99:626-633  
your personal reprint 


271

Costa JR, Jr., Abizaid A, Dudek D, Silber S, Leon MB, Stone GW.
Rationale and design of the MGuard for acute ST elevation reperfusion MASTER trial.
Catheter Cardiovasc Interv. 2013;82:184-190  
your personal reprint 


270

Bramlage P, Cuneo A, Zeymer U, Hochadel M, Richardt G, Silber S, Senges J, Nienaber CA, Tebbe U, Kuck KH.
Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents.
Clin Res Cardiol. 2013;102:289-297 
your personal reprint 


269

Silber S.
The RESOLUTE clinical programme: one month DAPT data presented at TCT
Confluence, Issue 6, 31 - 33, (2012)  
your personal reprint 


268

Labeit AM, Klotsche J, Pieper L, Pittrow D, Einsle F, Stalla GK, Lehnert H, Silber S, Zeiher AM, Marz W, Wehling M, Wittchen HU.
Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients.
PLoS One. 2012;7:e52229  
your personal reprint 


267

Vranckx P, Farooq V, Garg S, Van Es GA, Silber S, Windecker S, Stone GW, Serruys PW.
Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting.
Heart. 2012;98:1424-1430  
your personal reprint 


266

Stefanini GG, Kalesan B, Pilgrim T, Raber L, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S.
Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents.
JACC Cardiovasc Interv; 5:301-310 (2012) 
your personal reprint 


265

Van de Werf F, Ardissino D, Bueno H, Collet JP, Gershlick A, Kolh P, Kristensen SD, Silber S, Verheugt F, Wojakowski W.
Acute coronary syndromes: Considerations for improved acceptance and implementation of management guidelines.
Expert Rev Cardiovasc Ther; 10:489-503 (2012)  
your personal reprint 


264

Neumann FJ, Cremer J, Falk V, Reifart N, Silber S, Thielmann M.
Kommentar zu den gemeinsamen „Guidelines on Myocardial Revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS)
Der Kardiologe; 6: 94 – 104 (2012)  
your personal reprint 

Pocket Leitlinien Myokardrevaskularisation


263

Abdel-Wahab M, Nienaber CA, Mostafa AE, Ferenc M, Silber S, Sabin G, Tebbe U, Akin I, Hochadel M, Senges J, Kuck KH, Richardt G.
Treatment of coronary bifurcation lesions with drug-eluting stents: Insights from the first phase of the prospective multicenter german drug-eluting stent registry.
J Interv Cardiol. 2012;25:344-352  
your personal reprint 


262

Beijk MA, Damman P, Klomp M, Woudstra P, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter AR.
Twelve-month clinical outcomes after coronary stenting with the genous bio-engineered R stent in patients with a bifurcation lesion: From the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) registry.
Coronary Artery Disease; 23:201-207 (2012)  
your personal reprint 


261

Damman P, Klomp M, Silber S, Beijk MA, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous bio-engineered R stent in patients from the e-HEALING registry.
Catheter Cardiovasc Interv; 79:243-252 (2012)  
your personal reprint 


260

Klomp M, Damman P, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Applying the national institute for clinical excellence criteria to patients treated with the genous bio-engineered R stent: A sub-study of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry.
Heart Vessels; 27:360-369 (2012)  
your personal reprint 


259

Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Resting heart rate as a tool for risk stratification in primary care: Does it provide incremental prognostic information?
European Journal of Preventive Cardiology; 19:275-284 (2012)
your personal reprint 


258

Leistner DM, Klotsche J, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention.
Clin Chem; 58:200-208 (2012)  
your personal reprint 


257

Klomp M, Damman P, Beijk MA, Tan KH, Balian V, de Luca G, Tijssen JG, Silber S, de Winter RJ.
Differences in cardiovascular risk factors and clinical outcomes between western european and southeast asian patients treated with the genous bio-engineered R stent: An e-HEALING worldwide registry substudy.
Coronary Artery Disease; 23:271-277 (2012)  
your personal reprint 


256

Silber S, Tan HC, Iniguez A, Scacciatella P, Smith D, Kutryk M, Brugaletta S 
Relative clinical contraindications to the use of drug-eluting stents: what are the alternatives?
Cardiology International, 45 - 48 (2012)  
your personal reprint 


255

Schneider HJ, Klotsche J, Friedrich N, Schipf S, Volzke H, Silber S, Marz W, Nauck M, Pittrow D, Wehling M, Sievers C, Lehnert H, Stalla GK, Wittchen HU, Wallaschofski H.
Risk factors associated with the metabolic syndrome in abdominal obesity.
Clin Obes. 2012;2:142-149  
your personal reprint 


254

Silber S, Helms T, Berger H-J, Braun P, Hoffmann S, Schäfer A, Vester E.
Optimale Thrombozytenaggregationshemmung bei Patienten mit akutem Koronarsyndrom (ACS).
Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
1. Version, Frühjahr 2012
your personal reprint 


252

Nationale Versorgungsleitlinien der Bundesärztekammer, Kassenärztlichen Bundesvereinigung und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften zur chronischen koronaren Herzkrankheit
2011
www.versorgungsleitlinien.de


251

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK
Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the EURO HEART survey PCI registry.
Catheter Cardiovasc Interv; 78:702-709 (2011)  
your personal reprint 


250

Bauer T, Nienaber CA, Akin I, Kuck KH, Hochadel M, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Zahn R.
Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: Results from the German DES.DE-Registry.
Clin Res Cardiol; 100:701-709 (2011)
your personal reprint


249

Damman P, Iniguez A, Klomp M, Beijk M, Woudstra P, Silber S, Ribeiro EE, Suryapranata H, Sim KH, Tijssen JG, de Winter RJ.
Coronary stenting with the genous bio-engineered R stent in elderly patients.
Circ J; 75:2590-2597 (2011)
your personal reprint


248

Damman P, Klomp M, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ. 
Twelve-month outcomes after coronary stenting with the genous bio-engineered R stent in diabetic patients from the e-HEALING registry.
J Interv Cardiol; 24:285-294 (2011)
your personal reprint 


247

De Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, Silber S, Weidinger F, Wijns W, Zeymer U, Hamm C, Boersma E.
Euroheart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention.
Eur Heart J; 32:1398-1408 (2011)
your personal reprint 


246

den Dekker WK, Houtgraaf JH, Onuma Y, Benit E, de Winter RJ, Wijns W, Grisold M, Verheye S, Silber S, Teiger E, Rowland SM, Ligtenberg E, Hill J, Wiemer M, den Heijer P, Rensing BJ, Channon KM, Serruys PW, Duckers HJ.
Final results of the HEALING-IIb trial to evaluate a bio-engineered cd34 antibody coated stent (Genous stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients.
Atherosclerosis; 219:245-252 (2011)
your personal reprint


245

Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Van Remortel E, Ronden J, Windecker S.
The prognostic utility of the syntax score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial.
JACC Cardiovasc Interv; 4:432-441 (2011)  
your personal reprint 


244

Gomez-Lara J, Heo JH, Brugaletta S, Garg S, Garcia-Garcia HM, van Geuns RJ, Silber S, Windecker S, Serruys PW.
Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents.
Am Heart J; 162:1069-1079 e1062 (2011)
your personal reprint


243

Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbaek H, Saunamaki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nuesch E, Garcia-Garcia HM, Silber S, Windecker S, Serruys PW.
Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. A fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: An optical coherence tomography substudy from the resolute all comers trial.
Eur Heart J; 32:2454-2463 (2011)
your personal reprint


242

Schneider HJ, Klotsche J, Silber S, Stalla GK, Wittchen HU.
Measuring abdominal obesity: Effects of height on distribution of cardiometabolic risk factors risk using waist circumference and waist-to-height ratio.
Diabetes Care; 34:e7 (2011)
your personal reprint


241

Silber S, Damman P, Klomp M, Beijk MA, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Hian Sim K, Tijssen JG, de Winter RJ.
Clinical results after coronary stenting with the genous bio-engineered R stent: 12-month outcomes of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry.
EuroIntervention; 6:819-825 (2011)
your personal reprint


240

Silber S, Gutierrez-Chico JL, Behrens S, Witzenbichler B, Wiemer M, Hoffmann S, Slagboom T, Harald D, Suryapranata H, Nienaber C, Chevalier B, Serruys PW.
Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: The EUROSTAR-II randomised clinical trial.
EuroIntervention; 7:64-73 (2011)
your personal reprint


239

Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C.
Prasugrel in der Akut- und Nachbehandlung des akuten Koronarsyndroms: Wie ist der aktuelle Stand?
Dtsch Med Wochenschr; 136:782-785 (2011)  
your personal reprint 


238

Silber S, Windecker S, Vranckx P, Serruys PW. 
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the resolute all comers trial
Lancet; 377:1241-1247 (2011)  
your personal reprint 


237

Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S.
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention).
J Am Coll Cardiol; 57:2221-2232 (2011)
your personal reprint


236

Stella PR, Belkacemi A, Waksman R, Stahnke S, Torguson R, von Strandmann RP, Agostoni P, Sangiorgi G, Silber S. 
The VALENTINES trial: Results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation dior paclitaxel drug-eluting balloon for in-stent restenosis treatment.
EuroIntervention; 7:705-710 (2011)
your personal reprint


235

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK.
Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina.
Int J Cardiol; 151:164-169 (2011)
your personal reprint 


234

Silber S.
Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines
RMMJ; 2: e0056 (2011)  
your personal reprint 


233

Silber S,Van de Werf F. and Members of the Task Force
ESC/DGK Pocket-Leitlinie:
Akutes Koronarsyndrom mit persistierender ST- Streckenhebung (STEMI) 
Der Kardiologe; 4:93-106 (2010)
your personal reprint 


232

Silber S, Borggrefe M, Hasenfuß G, Falk V, Kastrati A, Weis M, Hamm CW.
Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI)
Der Kardiologe; 4:84-92 (2010)
your personal reprint 


231

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK.
Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: Impact of clinical status and procedural characteristics.
Clin Res Cardiol; 99:375-383 (2010)
your personal reprint


230

Mahabadi AA, Achenbach S, Burgstahler C, Dill T, Fischbach R, Knez A, Moshage W, Richartz BM, Ropers D, Schröder S, Silber S, Möhlenkamp S.
Safety, efficacy, and indications of beta-adrenergic receptor blockade to reduce heart rate prior to coronary ct angiography.
Radiology; 257:614-623 (2010)
your personal reprint


229

Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, Dorr M, Felix S, Lehnert H, Pittrow D, Silber S, Volzke H, Stalla GK, Wallaschofski H, Wittchen HU.
The predictive value of different measures of obesity for incident cardiovascular events and mortality.
J Clin Endocrinol Metab; 95:1777-1785 (2010)
your personal reprint


228

Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
N Engl J Med; 363:136-146 (2010) 
your personal reprint Originalarbeit
your personal reprint Appendix


227

Silber S. 
Evidenzbasiertes Vorgehen beim ST-Strecken- Hebungsinfarkt (STEMI): Neueste Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) 2010
Herz; 35:558-564 (2010)
your personal reprint


226

Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW.
Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies.
EuroIntervention; 5:871-874 (2010)
your personal reprint


225

Hoffmeister HH, Bode C, Darius H, Huber K, Rybak K, Silber S.
Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen
Positionspapier der Deutschen Gesellschaft für Kardiologie (DGK)
Der Kardiologe; 4: 365-374 (2010)
your personal reprint


224

Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D.
Guidelines on Myocardial Revascularization of the European Society of Cardiology (ESC)
Eur Heart J; 31:2501-2555 (2010)
your personal reprint
Eur J Cardiothorac Surg. 2010;38 Suppl:S1-S52
your personal reprint